Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Completes BioServe Buy

NEW YORK (GenomeWeb) – Cancer Genetics today announced the closing of its $1.9 million acquisition of Indian genomics and next-generation sequencing services company BioServe Biotechnologies.

The deal, which is being financed primarily with Cancer Genetics stock and other deferred considerations, was originally announced in May and provides the Rutherford, NJ-based cancer diagnostics firm access to an important and growing market for molecular diagnostics and oncology services, it said.

The firm noted that India has more than 1 million new cases of cancer each year with an incidence rate anticipated to rise by more than 72 percent by 2025. In a statement, Cancer Genetics CEO Panna Sharma said that the company anticipates wide adoption of its tests for non-Hodgkin's lymphomas and leukemias, kidney cancer, and cervical cancer.

"In particular, the acquisition positions [Cancer Genetics] to revolutionize cervical cancer screening and treatment in India, where 123,000 new cases are diagnosed annually," he said. "The expansion into India will also allow [the company] to leverage its resources and scale its operations, while strengthening its capabilities in molecular testing, DNA synthesis, biomarker analysis, and next-generation sequencing."

BioServe, which is being renamed Cancer Genetics India, will operate as a wholly owned subsidiary of Cancer Genetics. It has a 14,000-square-foot facility in Hyderabad, and has provided services to more than 200 clients, including Dr. Reddy's Laboratories, Natco Pharma, Piramal Life Sciences, the Indian Institute of Science Education, and India's Centre for Cellular and Molecular Biology.

Cancer Genetics said it plans to keep all 33 BioServe employees.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more